Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

SGLT2 inhibitor reduced HF outcomes independently of HF risk in diabetic patients

Sep. 19, 2017 - Fitchett D et al. - Eur Heart J 2017

Large outcomes trial confirms CV safety of GLP-1 analogue in T2DM at wide range of CV risk

Sep. 18, 2017 - news

PCSK9 inhibition also safely lowers CV event in patients with diabetes

Sep. 15, 2017 - news

SGLT2 inhibition in cardiology: What a cardiologist needs to know

Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

Dec. 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##SCROLLER_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

May 6, 2016 - Dubai, UAE - Dr Robert J Chilton

SGLT2 inhibitor reduced HF outcomes independently of HF risk in diabetic patients

Sep. 19, 2017 - Fitchett D et al. - Eur Heart J 2017

Many T2DM patients with established CVD and without HF are at high or very high risk for HF outcomes. Empagliflozin reduced adverse HF outcomes both in patients at low or high HF risk.

Large outcomes trial confirms CV safety of GLP-1 analogue in T2DM at wide range of CV risk

EASD 2017 -Lisbon, Portugal

Sep. 18, 2017 - news

EASD 2017 The EXSCEL trial results show that treatment with exenatide extended-release did not increase the risk of MACE and may reduce all-cause mortality in T2DM patients.

PCSK9 inhibition also safely lowers CV event in patients with diabetes

EASD 2017 - Lisbon, Portugal

Sep. 15, 2017 - news
FOURIER sub-analysis shows that lowering LDL-C levels with evolocumab significantly and consistently reduced CV events also in patients with diabetes, without increasing the risk of new onset diabetes in non- or pre-diabetics.

EASD 2017 FOURIER sub-analysis shows that lowering LDL-C levels with evolocumab significantly and consistently reduced CV events also in patients with diabetes, without increasing the risk of new onset diabetes in non- or pre-diabetics.

Thiazolidinedione and sulfonylureas have similar CV benefit for diabetics on top of metformin

Sep. 14, 2017 - Vaccaro O et al. - Lancet Diabetes Endocrinol 2017

In the TOSCA.IT trial, pioglitazone and sulfonylurea as add-on therapies to metformin were associated with similarly low rates of CV events and few clinically relevant side-effects in uncomplicated diabetic patients.

Six meals per day instead of three improves glucose control in obese people with diabetes

EASD 2017 - Lisbon Portugal

Sep. 14, 2017 - news
Obese people with prediabetes or diabetes showed better glucose control and were less hungry when taking six meals per day than with three, at an identical level of total calories.

EASD 2017 Obese people with prediabetes or diabetes showed better glucose control and were less hungry when taking six meals per day than with three, at an identical level of total calories.

Caffeine linked to lower risk of death in women with diabetes

EASD 2017 - Lisbon Portugal

Sep. 14, 2017 - news
 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.

EASD 2017 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.

Improved CV risk profile upon treatment with combination of insulin degludec/liraglutide in T2DM

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.

EASD 2017 A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.

Cognitive behavioral group therapy not better at preventing weight regain after dieting in T2DM

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.

EASD 2017 Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.

Room for improvement at risk factor management in transgender patients with diabetes

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.

EASD 2017 Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.

New NHS device helps loose weight and improve glucose regulation in obese T2DM patients

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.

EASD 2017 NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.

Clinical benefit of SGTL2 inhibitor in T2DM with CVD independent from background glucose control

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
Three subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.

EASD 2017 Subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.

More glucose and weight reductions with once-weekly GLP-1 analogue vs. comparator treatments

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.

EASD 2017 Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.